How do GLP-1 compounding restrictions affect 503B insurance?

The FDA resolution of the semaglutide and tirzepatide shortage status (in 2024-2025) and subsequent enforcement wave in early 2026 triggered carrier responses to GLP-1 compounding exposure. Several specialty pharmacy and 503B carriers added non-FDA-approved drug exclusions to renewal endorsement schedules - sometimes mid-policy, sometimes at renewal without prominent disclosure.

A 503B with GLP-1 revenue must verify that the renewal endorsement schedule does not silently exclude products liability for the GLP-1 line. The verification is mechanical: read every renewal endorsement, search for "non-FDA-approved," "compounded," "GLP-1," "semaglutide," or "tirzepatide" exclusion language, and document the result. If the exclusion is present, the GLP-1 revenue line is operating uninsured.

The markets still writing GLP-1 503B coverage are limited and the underwriting is materially tighter. Underwriters now require evidence of FDA shortage status documentation supporting continued production, patient-specific prescription tracking (for 503A scope), or 503B regulatory standing to operate non-patient-specific production. Premium is materially higher than pre-2025 baseline.